Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months
• To describe the immune response of each candidate vaccine 21 days after each vaccination by hemagglutination inhibition (HAI) and seroneutralization (SN) testing in all subjects. • To describe the a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-olds)
To demonstrate that administration of the 9-valent HPV L1 VLP vaccine induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 16 and anti-HPV 18 compared to GARDASIL in preadolescent and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Safety and Quality of Life study of Aflibercept in patients with metastatic Colorectal Cancer previously treated with an oxaliplatin-based regimen
To evaluate the safety of aflibercept in patients with metastatic Colorectal Cancer (mCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen (patients sim...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
DISRUPT : Essai de phase 2 randomisé, en double aveugle, évaluant l’efficacité d’une chimiothérapie par taxane et sel de platine associé ou non à l’ombrabuline, en traitement de 1ère ligne , chez des patients ayant un cancer du poumon non à petites cellules localement avancé ou métastatique. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de l’ajout de l’ombrabuline à une chimiothérapie associant un taxane et un sel de platine, chez des patients ayant un cancer du poumon non à petites ...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT), in overweight patients with additional risk factors
To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by CIMT.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TCD6595 : Essai de phase 2 évaluant l’association du XRP9881 au trastuzumab, chez des patientes ayant un cancer du sein HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC).
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months
To demonstrate the efficacy of QIV as compared to non-influenza vaccine
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
TELI CAP - Telithromycin in children with mild to moderate community-acquired pneumonia
To assess the steady state pharmacokinetics of telithromycin oral suspension (25 mg/kg once a day for 7-10 days), in children 6 months to less than 13 years of age (<13) with community acquired pneumo...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal or over 70 years of age
To demonstrate that a second dose of ZOSTAVAX elicits higher varicella-zostervirus (VZV) antibody titers than first dose of ZOSTAVAX whether given a 0-1 month schedule or as a 0-3 month schedule in su...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Aventis Deutschland GmbH
Update Il y a 4 ans
Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis
To assess the systemic exposure of icatibant after intra-articular injection
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
12
13
14
15
16
17
18
19
20
21
Next